DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as first-line therapy for patients with metastatic triple negative breast cancer for whom immunotherapy was not an option in TROPION-Breast02 Phase 3 trial

CAR-T Digest - August 2020

Weekly Digest - October 2025

06 October 2025: DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as first–line therapy for patients with metastatic triple negative breast cancer for whom immunotherapy was not an option in TROPION-Breast02 Phase 3 trial

DATROWAY (datopotamab deruxtecan), developed by Daiichi Sankyo and AstraZeneca, significantly improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy in the Phase 3 TROPION-Breast02 trial for patients with metastatic or inoperable triple-negative breast cancer (TNBC) not eligible for immunotherapy
It is the first and only therapy which has demonstrated a survival benefit over chemotherapy in this difficult-to-treat TNBC population
The safety profile was consistent with prior trials, and the companies plan to present detailed data at an upcoming medical meeting and pursue global regulatory submissions
Additional Phase 3 studies (TROPION-Breast03, TROPION-Breast04, and TROPION-Breast05) are ongoing to evaluate DATROWAY in various stages and treatment settings of TNBC, including combinations with durvalumab and comparisons to pembrolizumab plus chemotherapy